SP Industries, a designer and manufacturer of state-of-the-art laboratory equipment, pharmaceutical fill-finish manufacturing solutions, laboratory supplies and glassware, announced recently that it has acquired the assets of privately held i-Dositecno. Located in Mataro, Spain, i-Dositecno is a global provider of complete sterile filling lines for pharmaceutical, cosmetic and ophthalmic applications.
“i-Dositecno has a well-earned reputation for producing high quality, fill-finish equipment complemented by strong software engineering capabilities and innovative servicing and support,” stated SP CEO, Brian Larkin. “At SP we are continually focused on bringing value to our customer relationships and i-Dositecno’s current portfolio, engineering expertise and broad capabilities in liquid filling particularly for syringes and other cartridges in addition to vials, are a very strategic complement to our Hull and VirTis freeze dryers and PennTech aseptic vial processing lines,” he added.
Larkin continued by saying, “As biological drug development and treatment protocols have become more specialized, we expect short-run aseptic liquid filling to continue to drive pharmaceutical growth. With the addition of i-Dositecno to our SP brand, we now join a very select group of manufacturers with the capability to provide full lines. And, while SP has traditionally had a stronger equipment footprint in the United States, i-Dositecno’s efforts and success have primarily been within Europe and Asia. These relationships, as well as the addition of a Spain location to our current UK manufacturing within Europe provide significant opportunity to better serve the world-wide market.”
Accoring to a press release issued by the company, key manufacturing, engineering, sales and service personnel from i-Dositecno have joined the SP team to insure continuity in operations and service. Oriol Casoliva, founder and past CEO of i-Dositecno, will join SP’s Executive Leadership Team and is expected to be instrumental in maximizing i-Dositecno and SP’s performance within the aseptic pharmaceutical manufacturing space.